Miles Piper

Dec 31, 2024 | jitc.bmj.com | Jacob Gadwa |Justin Yu |Miles Piper |Michael W. Knitz

MethodsMurine MOC2 and P029 HNSCC and PK5L1940 pancreatic cell lines were used for in vivo studies. All cells were cultured at 37°C and 5% CO2 in appropriate media; DMEM-F12:IMDM (1:2) supplemented with 10% FBS and 1% primocin/fungin (InvivoGen), 1.75 µg EGF, 20 µg hydrocortisone, and 0.1% insulin for MOC2; DMEM-F12 supplemented with 10% FBS and 1% primocin/fungin for P029; RPMI1640 supplemented with 10% FBS and 1% primocin/fungin for PK5L1940.

Sep 22, 2024 | biorxiv.org | Miles Piper |Jacob Gadwa |Chloe Hodgson |Michael M. Knitz

AbstractBackground: This work seeks to understand whether IL15-incorporating treatments improve response to radiotherapy and uncover mechanistic rationale for overcoming resistance to IL15 agonism using novel therapeutic combinations. Experimental Design: Orthotopic tumor models of PDAC were used to determine response to treatment. IL15-/- and Rag1-/- mouse models were employed to determine dependence on IL15 and CTLs, respectively.

Sep 10, 2024 | biorxiv.org | Sana D. Karam |Jacob Gadwa |Justin Yu |Miles Piper

AbstractBackground: Treatment with immunotherapy can elicit varying responses across cancer types, and the mechanistic underpinnings that contribute to response vs. progression remain poorly understood. However, to date there are few preclinical models that accurately represent these disparate disease scenarios.